observed that RAS-activating mutations (HRAS/KRAS) are not very common in patients with cetuximab-naive HNSCC, while after treatment with cetuximab, one-third of patients developed acquired mutations in KRAS, NRAS, and HRAS. The gene discussed is KRAS; the disease is head and neck squamous cell carcinoma.